在人体盐敏感高血压中,eicosanoid-regulated myeloid ENaC和isolevuglandin形成
Lale A Ertuglu1, Ashley Pitzer Mutchler2, Sydney Jamison2,3
1Division of Nephrology, Department of Medicine (L.A.E., T.A.I.), Vanderbilt University Medical Center, Nashville, TN.
Hypertension (Dallas, Tex. : 1979)
|September 7, 2023
概括
高盐摄入量会通过在抗原呈现细胞 (APC) 中的异黄兰丁生产,增加盐敏感个体的血压. 环氧乙酸 (EETs) 可能调节这个过程,为盐敏感性提供潜在的诊断标记物.
科学领域:
- 心血管研究的心血管研究.
- 脏生理学 脏生理学
- 免疫学 免疫学 免疫学
背景情况:
- 对盐敏感个体的盐诱导高血压的机制尚未完全理解.
- 之前的研究将高摄入量,表皮道,isolevuglandins和高血压联系在一起.
- 这项研究研究了环氧乙酸 (EETs) 在调节抗原呈现细胞 (APC) 中的异黄兰丁形成中的作用及其与盐敏感高血压的联系.
研究的目的:
- 测试EETs调节APC中的表皮道依赖性isolevuglandin-adduct形成的假设,从而导致人类对盐敏感的高血压.
- 探索盐敏感性的潜在诊断标记.
主要方法:
- 一项机制性临床研究,涉及19名高血压患者.
- 住院患者的盐加载和耗尽协议,以评估盐的敏感性.
- 在APC中通过流细胞测量对isolevuglandin-adducts的分析.
- 血液单核细胞的基因表达分析.
- 使用液体染色体质谱法测量血和尿液EETs.
主要成果:
- 基线异黄兰丁阳性APC与较高的盐敏感性相关.
- 在对盐敏感的个体中,与盐耗尽一起,异黄兰丁阳性APCs下降.
- 在APC中,表达上皮质道三角子单元,SGK1和CYP2S1.1.
- 尿中的14,15-EET水平与盐敏感性相关.
- 14,15-EET抑制了APC中的高盐诱导的伊索列夫格兰丁的产生.
结论:
- 在APC中,异黄素的产生对盐敏感个体的盐摄入量变化做出反应,可能由脏14,15-EET调节.
- 在没有盐加载协议的情况下,基线异黄兰丁阳性APC和尿路14,15-EET可以作为盐敏感性的诊断工具.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
687
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
687
01:33Hormonal Regulation
33.2K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.2K
01:17Hormonal Regulation of Blood Pressure
2.7K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
2.7K
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
776
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
776
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460